98814-60-9 Usage
Uses
Used in Pharmaceutical Industry:
5,10-DiforMyl-5,6,7,8-tetrahydro Folic Acid is used as an active pharmaceutical ingredient for the development of medications targeting various health conditions. Its role in primary metabolism and one-carbon unit transfer makes it a valuable compound for therapeutic applications.
Used in Nutritional Supplements:
5,10-DiforMyl-5,6,7,8-tetrahydro Folic Acid is used as a key component in nutritional supplements to support overall health and well-being. Its involvement in essential metabolic reactions helps maintain proper bodily functions and contributes to a balanced diet.
Used in Research and Development:
5,10-DiforMyl-5,6,7,8-tetrahydro Folic Acid is utilized in research and development for studying its potential applications in various fields, such as medicine, nutrition, and biotechnology. Its unique properties and role in one-carbon unit transfer make it an interesting subject for scientific exploration.
Check Digit Verification of cas no
The CAS Registry Mumber 98814-60-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,8,8,1 and 4 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 98814-60:
(7*9)+(6*8)+(5*8)+(4*1)+(3*4)+(2*6)+(1*0)=179
179 % 10 = 9
So 98814-60-9 is a valid CAS Registry Number.
98814-60-9Relevant academic research and scientific papers
Stereochemistry of Reduction of the Vitamin Folic acid by Dihydrofolate Reductase
Charlton, Peter A.,Young, Douglas W.,Birdsall, Berry,Feeney, James,Roberts, Gordon C. K.
, p. 1349 - 1354 (2007/10/02)
Reduction of the vitamin folic acid (6) to the coenzyme 5,6,7,8-tetrahydrofolic acid (1) by the enzyme dihydrofolate reductase is shown to involve transfer of the 4-pro R hydrogen of NADPH to the same face at both C-6 and C-7 of the pteridine system (the re face at C-6 and the si face at C-7).The orientations of the pteridine system of folic acid (6) and of dihydrofolic acid (5) when bound to the enzyme are different from the orientation of the pteridine ring of the anti-cancer drug methotrexate (11) when bound to this enzyme.
